Composition for the treatment of progressive renal diseases
Inventors
BERNACHON, Natalia • Monginoux, Patricia
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10149895-B2
Publication Date
2018-12-11
Expiration Date
Abstract
Described herein is an association of at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive antihypertensive agent and at least one antifibrotic agent for the management of progressive renal diseases including chronic kidney diseases (CKD) in domestic carnivores. Specifically, the application describes veterinarian compositions comprising such an association and the use thereof for the treatment of CKD conditions.
Core Innovation
The invention relates to veterinary compositions and methods for managing progressive renal disease and chronic kidney disease (CKD) in domestic carnivores, particularly cats. The problem addressed is progressive renal disease/CKD in domestic animals, including chronic kidney disease, chronic renal failure, chronic renal disease, kidney insufficiency, kidney failure, and azotemia.
The method administers an association comprising at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive anti-hypertensive agent, and at least one antifibrotic agent. The association is formulated to be sufficient to induce a decrease in serum creatinine concentration in the domestic animal.
In the cat embodiment, the association further comprises a mixture of calcium carbonate and magnesium carbonate having a calcium carbonate to magnesium carbonate ratio between 3:1 and 4:1. The disclosed technical intent includes improving CKD markers, including an unexpected decrease in serum creatinine while also reducing phosphorus/BUN, and maintaining safety with no undesirable increase in calcium or magnesium.
Claims Coverage
The partial claim set includes two independent claims that share a multi-component treatment association and a defined calcium carbonate/magnesium carbonate ratio for cats, with each independent claim tailored to the target condition(s). The main inventive features cover the specific association of four functional agent classes, a serum creatinine decrease as an outcome criterion, and the defined CaCO3:MgCO3 mixture ratio, with cat as the domestic animal limitation.
Multi-component association sufficient to decrease serum creatinine
Administering an association comprising at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive anti-hypertensive agent and at least one antifibrotic agent sufficient to induce a decrease in serum creatinine concentration.
Calcium carbonate and magnesium carbonate mixture ratio between 3:1 and 4:1
Wherein the association comprises a mixture of calcium carbonate and magnesium carbonate in the ratio of calcium carbonate to magnesium carbonate of between 3:1 and 4:1.
Cat limitation for treating progressive renal disease and/or high blood pressure
Wherein the domestic animal is a cat, in a method of treating a domestic animal for high blood pressure and/or progressive renal disease.
Cat limitation for treating CKD and related kidney failure conditions
Wherein the domestic animal is a cat, in a method of treating chronic kidney disease (CKD), chronic renal failure (CRF), chronic renal disease, kidney insufficiency, kidney failure or azotemia.
Across both independent claims, the inventive concept is administering to a cat an association that includes phosphate binders, uremic toxin binders, a vasoactive anti-hypertensive agent, and an antifibrotic agent sufficient to induce decreased serum creatinine, with the association further requiring a calcium carbonate to magnesium carbonate ratio between 3:1 and 4:1.
Stated Advantages
Induces a decrease in serum creatinine concentration.
Improves CKD markers, including an unexpected decrease in serum creatinine.
Reduces phosphorus/BUN.
No undesirable increase in serum calcium or serum magnesium.
Documented Applications
Managing progressive renal disease and chronic kidney disease (CKD) in domestic carnivores, especially cats.
Treatment of high blood pressure and/or progressive renal disease in a domestic animal, with the domestic animal being a cat.
Treatment of chronic kidney disease (CKD), chronic renal failure (CRF), chronic renal disease, kidney insufficiency, kidney failure, or azotemia in a domestic animal, with the domestic animal being a cat.
Interested in licensing this patent?